October 2006 Briefing - Dermatology
Here are what the editors at HealthDay consider to be the most important developments in Dermatology for October 2006. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Fat Reduction Enhances Cancer Cell Death in Mice
FRIDAY, Oct. 27 (HealthDay News) -- Exercise or surgical fat removal stimulate the death of damaged skin and skin cancer cells in mice, suggesting that fat cells promote carcinogenesis by blocking the death of damaged cells, according to the results of a study published online Oct. 23 in the Proceedings of the National Academy of Sciences Early Edition.
CDC Recommends Shingles Vaccine for Older Patients
FRIDAY, Oct. 27 (HealthDay News) -- People aged 60 and older should be vaccinated against the Varicella zoster virus to reduce the likelihood of developing shingles, according to a recommendation made by the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices.
Topical Estradiol Can Be Transferred by Skin Contact
FRIDAY, Oct. 27 (HealthDay News) -- One hour after topical estradiol has been applied, a clinically significant transfer of the drug can occur during 15 minutes of skin contact, according to a report in the October issue of the Journal of Investigative Dermatology.
EGF Gene Potential Marker for Melanoma Survival
THURSDAY, Oct. 26 (HealthDay News) -- Epidermal growth factor (EGF) A61G polymorphism is a potential marker for more aggressive malignant melanoma and can predict earlier progression with shorter disease-free periods, according to study findings published in the October issue of the Journal of Investigative Dermatology.
Rituximab Helps with Refractory Pemphigus Vulgaris
WEDNESDAY, Oct. 25 (HealthDay News) -- Intravenous immune globulin combined with 10 infusions of rituximab during a five-month period can quickly and safely induce remission among patients with refractory pemphigus vulgaris, according to a study published in the Oct. 26 issue of the New England Journal of Medicine.
Lymphoma Risk Low Among Psoriasis Patients
WEDNESDAY, Oct. 25 (HealthDay News) -- Although patients with psoriasis have a higher relative risk of lymphoma, the absolute risk remains low because the disease is rare and the magnitude of association is small, according to a report in the October issue of the Journal of Investigative Dermatology.
Sensitivity to Ladybug Allergen More Common Than Thought
TUESDAY, Oct. 24 (HealthDay News) -- Ladybug allergies are apparently more common than once thought, according to three reports in the October issue of the Annals of Allergy, Asthma & Immunology that describe adults and children with high sensitivity for ladybug allergens.
Clinical, Pathology Diagnoses of Keratoses May Not Agree
FRIDAY, Oct. 20 (HealthDay News) -- Lesions clinically diagnosed as actinic keratoses agree with histopathology in more than 90 percent of cases, although histology shows that about one in 25 cases are squamous cell carcinoma, according to a study in the October issue of Dermatologic Surgery.
Cream Plus Laser Is Safe, Effective for Unwanted Hair
THURSDAY, Oct. 19 (HealthDay News) -- A combination of eflornithine hydrochloride cream (Vaniqa) and laser therapy is safe and results in more rapid removal of unwanted facial hair than laser therapy alone, according to a study in the October issue of the journal Dermatologic Surgery.
Postmastectomy Reconstruction Safe for Breast Cancer
THURSDAY, Oct. 19 (HealthDay News) -- Breast cancer patients requiring radiotherapy who undergo reconstructive surgery at the time of mastectomy have no more complications than those who do not have reconstructive surgery, researchers report in the October issue of Plastic and Reconstructive Surgery.
Trigeminal Neuralgia Case Linked to Tongue Piercing
WEDNESDAY, Oct. 18 (HealthDay News) -- An 18-year-old woman who presented with a two-month history of neuropathic facial pain that she described as "electrical shocks" was found to have atypical trigeminal neuralgia due to a recent tongue piercing, according to a research letter published in the Oct. 18 issue of the Journal of the American Medical Association.
In-Office Treatment Safe for Non-Melanoma Skin Cancer
WEDNESDAY, Oct. 18 (HealthDay News) -- Non-melanoma skin cancer should be managed in an office-based setting because it is more cost-efficient, according to the results of a study published in the October issue of Dermatologic Surgery.
Toenail Fungus Can Be Reservoir for Skin Mycosis
TUESDAY, Oct. 17 (HealthDay News) -- Treatment of toenail onychomycosis may not only cure toenail lesions but could be critical in preventing the spread of disease to other body sites, according to research published in the October issue of the Archives of Dermatology.
Adult Beachgoers Accurately Report Exposure to Sun
TUESDAY, Oct. 17 (HealthDay News) -- Adult sunbathers are generally accurate in their self-reporting of sun exposure, sunscreen use and clothing worn, according to a report published in the October issue of the Archives of Dermatology.
Toenail Fungus Test Is Both Accurate and Affordable
THURSDAY, Oct. 12 (HealthDay News) -- The best diagnostic test for toenail onychomycosis is potassium hydroxide preparation with chlorazol black E (KOH-CBE) due to a combination of test sensitivity and cost-effectiveness, researchers report in the October issue of the Journal of the American Academy of Dermatology.
More Efforts Needed to Reduce U.S. Sunburn Rates
THURSDAY, Oct. 12 (HealthDay News) -- Rates of sunburn in the United States are very high, with risk of sunburn highest among younger adults and those with higher education and incomes, according to a study in the October issue of the Journal of the American Academy of Dermatology.
Antisense Drug May Help in Metastatic Melanoma
WEDNESDAY, Oct. 11 (HealthDay News) -- Adding the antisense oligonucleotide drug, oblimersen, to dacarbazine therapy may increase survival among patients with advanced melanoma, particularly those with normal baseline serum lactate dehydrogenase, researchers report in the Oct. 10 issue of the Journal of Clinical Oncology.
One-Third of Psoriasis Patients Fail to Adhere to Therapy
WEDNESDAY, Oct. 11 (HealthDay News) -- Psoriasis patients do not adhere to topical corticosteroid therapy because they are dissatisfied with the results, fearful of side effects or find the treatment inconvenient, according to the results of a study published in the October issue of the Journal of the American Academy of Dermatology.
Psoriasis Associated with Myocardial Infarction Risk
TUESDAY, Oct. 10 (HealthDay News) -- Psoriasis may increase the risk of having a myocardial infarction, particularly in younger patients with severe disease, according to study results published in the Oct. 11 issue of the Journal of the American Medical Association.
U.S. Leprosy Case Linked to Exposure to Armadillos
TUESDAY, Oct. 10 (HealthDay News) -- A 57-year-old woman living in the state of Georgia developed borderline tuberculoid leprosy (Hansen's disease) due to exposure to armadillos, which burrowed in a garden where she worked, according to a report published in the October issue of the Journal of the American Academy of Dermatology. The woman had not traveled outside the United States, and had not been in any contact with known cases of leprosy.
FDA Approves New Drug for Intractable Skin Cancers
MONDAY, Oct. 9 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new skin cancer drug, Zolinza, for the treatment of persistent cutaneous T-cell lymphoma. Zolinza (vorinostat) is made by Pantheon, Inc., of Mississauga, Ontario, Canada, for Merck & Co., Inc.
Isotretinoin iPLEDGE Risk Management Program Revised
MONDAY, Oct. 9 (HealthDay News) -- The U.S Food and Drug Administration and the iPLEDGE program of Conshohocken, Penn., has announced a change to its iPLEDGE risk management program for isotretinoin that will make it easier for some patients to fill repeat prescriptions of the acne treatment. The program, which aims to reduce the risk of fetal exposure to isotretinoin, has eliminated its 23-day lock-out period for males and females of non-childbearing potential.